Lifeboat Foundation

Because crises shape history, there are hundreds of thinkers who have devoted their lives to studying how they unfold. This work – what we might call the field of “crisis studies” – charts how, whenever crisis visits a given community, the fundamental reality of that community is laid bare. Who has more and who has less. Where the power lies. What people treasure and what they fear.

Times of upheaval are always times of radical change. Some believe the pandemic is a once-in-a-generation chance to remake society and build a better future. Others fear it may only make existing injustices worse. By Peter C Baker.

Staffing shortages amid the 386,000 VA employees are “a root cause for many of the problems in veterans’ care,” said Inspector General Michael Missal.

There are two main reasons for the shortages — low salaries and a lack of qualified applicants, with the former leading to the latter.

Consider this item from the report: VA “medical center directors make approximately 25% of a private sector hospital chief executive officer salary yet have a greater scope of responsibility.” Top pay for a VA medical center director is $201,900.

Casdin Capital’s Eli Casdin highlights seven promising life-sciences stocks, including bluebird bio, Invitae, and Crispr Therapeutics.

Designer Babies

Xenobots, which were first brought to life back in January, can’t reproduce. Instead, computer scientists program them in a virtual environment and then 3D print their creations out of embryonic cells.

“We are witnessing almost the birth of a new discipline of synthetic organisms,” Columbia University roboticist Hod Lipson, who was not part of the research team, told the NYT. “I don’t know if that’s robotics, or zoology or something else.”

Employees at Jeff Bezos’ aerospace firm Blue Origin are outraged that senior leadership is pressuring workers to conduct a test launch of the company’s New Shepard rocket — designed to take wealthy tourists into space — while the COVID-19 pandemic devastates the United States.

To conduct the flight, Blue Origin officials are considering transporting employees from the company’s main headquarters in Kent, Washington — a town near Seattle where COVID-19 cases have surged — to a small town in West Texas called Van Horn. The town, which has a population of just over 2,000, is home to Blue Origin’s test launch facility where the company has conducted all past flights of the New Shepard rocket.

Many employees fear that traveling to Van Horn might expose them to the novel coronavirus and inadvertently introduce COVID-19 to the residents of the rural town where there is very little infrastructure to handle an outbreak. The Verge spoke exclusively with four Blue Origin employees who all asked to remain anonymous for fear of retaliation from the company. They say they are frustrated by the company’s desire to conduct a launch, as it could unnecessarily jeopardize the health of employees at Blue Origin and residents of Van Horn.

Shared by Michael Michalchik

Ivermectin is an inhibitor of the COVID-19 causative virus (SARS-CoV-2) in vitro.

• A single treatment able to effect ∼5000-fold reduction in virus at 48h in cell culture.

Continue reading “The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro” »

Our goal is to evaluate, test and share the validated & most promising Maker projects to create an alternative system to supply medical materials.

Studies of hibernating animals suggest that the molecular and synaptic integrity of neurons in the cerebral cortex that underlie self and consciousness is maintained in many cases when from the outside the brain appears dead.

A striking feature of medicine over the past few centuries has been our growing ability to bring people back from the “dead.” For most of human history, patients who were unconscious and not breathing were treated as though they had died. But the concept of resuscitation emerged as doctors grew to understand the basic function of the lungs and airways. That led to new techniques and tools capable of restoring both breathing and heartbeat — and the realization that cardiac arrest was not always a death sentence. That, in turn, gave rise to a distinction between what’s now called clinical death versus brain death.

Continue reading “‘Rebooting the brain’: Our fight to bring people back from the dead” »

The U.S. Food and Drug Administration (FDA) approved the first blood test that looks for the antibodies against the novel coronavirus that causes COVID-19. This is different than assays that test for presence of the virus—those test to determine if a patient has COVID-19. These new antibody tests determine if the person was exposed to the virus, had COVID-19 and recovered. And it suggests, if positive, that the person is now immune to COVID-19 and can’t get it again.

Research Triangle Park, North Carolina-based Cellex was granted an emergency use authorization (EUA) on its test yesterday.

The test is performed on a blood sample taken from a patient’s vein and can be performed by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), the Health and Human Services division that oversees clinical diagnostic testing in the United States.